EUCTR2013-000357-41-IE进行中（未招募）1 期
Identification of the Microbiota Dependent Response to Rifaximin in Irritable Bowel Syndrome Patients
The Alimentary Pharmabiotic Centre, University College Cork0 个研究点目标入组 80 人开始时间: 2013年6月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects aged 18 and < 65 at the time of the screening visit.
- •2. IBS as defined by Rome III criteria.
- •3. Clinical laboratory tests at screening showing no clinically significant abnormalities in the opinion of the Investigator.
- •4. Signed and dated written informed consent prior to admission to the study.
- •5. Able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.
- •6. Female subject is currently either of:
- •non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or any female who is surgically sterilized (via documented hysterectomy or bilateral tubal ligation). (For purposes of this study, postmenopausal is defined as one year without menses)
- •child bearing potential, the subject is eligible to enter and participate in this study if she is not lactating and has a negative pregnancy test both at screening (serum ?-HCG negative) and baseline (urine) prior to investigational product administration at visits 2, follow up on visits 3 and 4. The subject must also agree to one of the following methods of contraception:
- •i. Complete abstinence from intercourse two weeks prior to administration of study drug, throughout the clinical trial, until the completion of follow-up procedures or for two weeks following discontinuation of the study medication in cases where subject discontinues the study prematurely. (Subjects utilizing this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding 2 weeks when they present to the clinic for the Final Visit.) or,
- •ii. Has a male sexual partner who is surgically sterilized prior to the Screen Visit and is the only male sexual partner for that subject or,
- •iii. Sexual partner(s) is/are exclusively female or,
- •iv. Oral contraceptives (either combined or progestogen only) with double-barrier method of contraception consisting of spermicide with either condom or diaphragm. (Women of child-bearing potential using an oral contraceptive in combination with a double-barrier method of contraception are required to continue to use this form of contraception until the end of their oral contraceptive pill packet following discontinuation of study medication).
- •v. Use of double-barrier contraception, specifically, a spermicide plus a mechanical barrier (e.g. male condom, female diaphragm). The subject must be using this method for at least 1 week following the end of the study or,
- •vi. Use of any intrauterine device (IUD) with published data showing that the highest expected failure rate is less than 1% per year. The subject must have the device inserted at least 2 weeks prior to the first Screen Visit, throughout the study, and 2 weeks following the end of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. As a result of any of the medical interview, physical examination, evaluation of mental state and psychiatric history or screening investigations the physician responsible considers the subject unfit for the study.
- •2. Subjects who are pregnant or nursing.
- •3. Evidence of a biochemical or structural abnormality of the digestive tract. These conditions include (but not limited to):
- •Current evidence, or history of (at any time in the past);
- •inflammatory bowel disease (Crohn's disease or ulcerative colitis)
- •Lactose intolerance, not on a stable diet
- •Celiac Disease
- •laxative abuse (in the clinical judgement of the physician)
- •gastrointestinal surgery (exceptions include 6 months post-surgery for appendectomy, cholecystectomy, fundoplication without gas bloat, or hiatal hernia repair; 3 months post-surgery for herniorrhaphy without bowel resection)
- •gastroparesis
- •GI malignancy
- •carcinoid syndrome
- •amyloidosis
- •chronic pancreatitis
- •symptomatic gastrointestinal adhesions
- •toxic megacolon
- •gastrointestinal perforation
- •gastrointestinal obstruction and/or stricture.
- •4. Current evidence of or occurrence within the past 6 months of:
- •diverticulitis
- •symptomatic cholelithiasis
- •proctitis.
- •5. Subjects who have taken any medication for the treatment of IBS within 1 month prior to screening except for anti-diarrhoeal medications or laxatives for control of bowel habit which are allowed if at a stable dose for 2 weeks prior to randomisation.
- •6. Subject is currently taking any prohibited medication, including antibiotics (within 3 month prior to screening)
- •7. Subjects who are taking NSAIDs including aspirin on a regular basis or within 48 hours of a study day.
- •8. Systemic or inhaled corticosteroids (Note: topical (e.g. nasal steroid) are allowed).
- •9. The subject has received an investigational drug or participated in any other research trial within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.
- •10. History or presence of allergy to the study drug or drugs of this class, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
- •11. Any other clinically significant laboratory abnormality.
- •12. Any evidence of or treatment of malignancy (other than localized basal cell, squamous cell skin cancer or in situ uterine cervix cancer that has been resected) within the previous 5 years.
研究者
相似试验
招募中
不适用
Identification of Biomarkers and Microbiota Specific for Plaque Erosion and Layered Plaque in Patients with Acute Coronary Syndromes: A prospective OCT studyAcute coronary syndromeJPRN-UMIN000047254Massachusetts General Hospital100
招募中
不适用
The analysis of the microbiota as biomarkers of response to anticancer drugs in metastatic solid cancersJPRN-UMIN000030778Department of Internal Medicine, Division of Medical Oncology, Showa University School of Medicine.60
已完成
不适用
The bacteria associated with periodontal disease before and after treatment.Infection - Studies of infection and infectious agentsInflammatory and Immune System - Other inflammatory or immune system disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonPeriodontitisACTRN12619001307190Samantha Byrne15
招募中
不适用
Examination of the correlation between microbiota and disease in patients with atopic dermatitis and food allergyJPRN-UMIN000037869Juntendo university school of medicine Department of gastroenterology300
进行中（未招募）
不适用
Do resident microorganisms on human skin affect the sunburn response?DermatologySkin and Connective Tissue DiseasesISRCTN16557401niversity of Manchester16